LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3
About Study 19
Study 19 was a randomised, double-blind, placebo-controlled phase II clinical trial.2
In Study 19, Lynparza as maintenance treatment met the primary endpoint of improving PFS in the overall study population.2
A retrospective analysis was conducted on a pre-defined subgroup of patients with BRCA mutations. This is included 51% of patients N=136.3
**Platinum-sensitive defined by a relapse-free period of ~6 months following a response to the final dose of platinum-based chemotherapy treatment.